GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Novartis NOVN.SW · CHF

Health Care · Pharmaceuticals · SIX · 🇨🇭 Switzerland

Compare

133.46

+0.29%

Close of 9 Nov 2026, in CHF

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$46.49bn

FY2016FY2025

Net income

$11.92bn

FY2016FY2025

Free cash flow

$15.00bn

FY2016FY2025

Shareholders' equity

$37.52bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$46.49bn$42.10bn$37.98bn$35.37bn$35.79bn$40.61bn$39.62bn$37.52bn$35.33bn$40.24bn
Gross profit$34.88bn$31.66bn$27.83bn$25.95bn$26.24bn$28.30bn$27.88bn$25.71bn$24.23bn$25.98bn
Research and development$9.11bn$8.16bn$9.25bn$7.46bn$7.03bn$7.31bn$7.65bn$6.91bn$6.83bn$7.36bn
Operating income$14.48bn$11.84bn$7.95bn$6.47bn$8.91bn$8.75bn$7.39bn$6.84bn$7.65bn$6.73bn
Net income$11.92bn$9.72bn$12.09bn$5.66bn$19.55bn$6.57bn$9.55bn$10.26bn$6.27bn$5.46bn
Diluted earnings per share6.184.855.852.638.682.884.174.382.672.28

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$94.00bn$83.22bn$81.34bn$95.59bn$107.27bn$104.00bn$96.34bn$118.47bn$108.31bn$105.91bn
Cash and short-term investments$9.43bn$10.87bn$11.36bn$15.15bn$22.88bn$9.19bn$9.14bn$12.99bn$7.72bn$6.33bn
Total liabilities$56.14bn$47.30bn$43.29bn$47.23bn$52.07bn$57.88bn$51.13bn$54.43bn$47.90bn$44.95bn
Debt$35.38bn$31.26bn$26.35bn$27.91bn$31.02bn$37.85bn$29.15bn$32.09bn$28.43bn$23.69bn
Shareholders' equity$37.52bn$35.85bn$37.98bn$48.30bn$55.06bn$46.06bn$45.15bn$63.98bn$60.36bn$60.90bn
Shares outstanding1,929m2,004m2,065m2,150m2,253m2,282m2,292m2,341m2,348m2,395m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$16.32bn$14.34bn$11.77bn$11.59bn$12.27bn$11.11bn$11.09bn$11.62bn$10.27bn$9.34bn
Capital spending−$1.32bn−$3.10bn−$2.24bn−$2.17bn−$2.42bn−$2.10bn−$1.84bn−$2.73bn−$2.23bn−$2.34bn
Free cash flow$15.00bn$11.24bn$9.53bn$9.41bn$9.85bn$9.01bn$9.25bn$8.89bn$8.04bn$7.00bn
Dividends paid−$6.67bn−$6.21bn−$5.90bn−$6.11bn−$6.00bn−$5.69bn−$5.41bn−$5.67bn−$5.29bn−$5.27bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$11.52bn$10.44bn$10.94bn$11.69bn$14.84bn$11.09bn$11.03bn$10.72bn
Gross profit$8.58bn$7.70bn$8.04bn$8.81bn$11.51bn$8.46bn$8.33bn$8.09bn
Operating income$3.78bn$3.30bn$2.89bn$3.66bn$4.86bn$3.80bn$2.87bn$2.95bn
Net income$2.61bn$2.51bn$1.98bn$3.20bn$4.04bn$2.93bn$2.29bn$2.60bn
Diluted earnings per share1.361.311.021.662.091.521.141.30
Cash from operations$4.69bn$2.93bn$1.75bn$5.35bn$6.66bn$2.97bn$3.41bn$5.12bn
Capital spending−$256.0m−$275.0m−$509.0m−$676.0m−$558.0m−$206.0m−$920.0m−$650.0m
Free cash flow$4.44bn$2.65bn$1.24bn$4.67bn$6.11bn$2.76bn$2.49bn$4.47bn
Total assets$99.59bn$96.76bn$94.00bn$87.32bn$104.39bn$81.34bn$83.22bn$84.26bn
Cash and short-term investments$6.28bn$5.70bn$9.43bn$7.94bn$7.00bn$5.86bn$10.87bn$11.41bn
Debt$8.05bn$36.92bn$28.79bn$26.06bn$32.64bn$25.45bn$25.44bn$24.87bn
Shareholders' equity$33.90bn$31.44bn$37.52bn$36.08bn$41.98bn$31.23bn$35.85bn$35.26bn

Financial ratios

Data as of 3 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin75.0%75.2%73.3%73.4%73.3%69.7%
Operating margin31.2%28.1%20.9%18.3%24.9%21.5%
Net margin25.6%23.1%31.8%16.0%54.6%16.2%
Return on equity31.8%27.1%31.8%11.7%35.5%14.3%
Return on assets12.7%11.7%14.9%5.9%18.2%6.3%
Free cash flow yield8.6%8.2%6.4%6.0%6.1%5.4%
Revenue growth10.4%10.8%7.4%-1.2%-11.9%2.5%
Earnings growth22.7%-19.6%113.5%-71.0%197.6%-31.2%
Current ratio1.12x1.04x1.16x1.29x1.51x0.90x
Debt to equity0.73x0.67x0.53x0.44x0.43x0.64x
Equity ratio39.9%43.1%46.7%50.5%51.3%44.3%
Interest coverage14.38x14.46x10.65x9.24x12.10x10.99x
R&D as a share of sales19.6%19.4%24.4%21.1%19.7%18.0%
Buybacks as a share of market value3.7%3.0%4.0%4.6%1.3%0.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue9.5%2.7%1.3%
Operating income30.8%10.6%7.1%
Net income28.2%12.7%-1.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin75.1%74.3%73.4%70.7%
Operating margin29.7%25.2%24.5%21.8%
Net margin24.4%24.3%27.5%25.8%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings22.523.818.839.111.435.827.220.933.635.4
Price to sales5.85.56.06.36.25.86.55.76.04.8

Dividends and splits

Per share, in the currency the company pays

Paid for 29 years. Last went ex-dividend on 10 Mar 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year3.703.503.302.6672.5832.502.4582.375
  • 6-for-5 split · 4 Oct 2023
  • 1-to-1 reverse split · 11 Jul 2005
  • 40-to-1 reverse split · 7 May 2001
  • 1-to-1 reverse split · 3 May 1999

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.